Botox USA vs Korea differs less in the drug than in the system around it. Both countries use botulinum toxin type A, but each regulator licenses its own list of brands and uses, each manufacturer measures units on its own scale, and the review visit after treatment is a short drive at home yet an ocean away after a Jeju stay. Allergan's Botox and Merz's Xeomin are licensed in both markets, and Daewoong's Nabota is sold in the US as Jeuveau. Other Korean brands hold a Korean license alone. Crow's feet trials give a clear worked example of how products are compared.
Guide
Side by side: the parts of a toxin visit that change at the border
Some things stay put when you fly. The toxin blocks the nerve signal to the muscle it reaches, the effect appears over several days, and it fades over a few months. What shifts is the system around the drug. The table shows common patterns, not fixed rules.
| Point of difference | Typical US pattern | Typical pattern on a Jeju visit |
|---|---|---|
| Licensing body | Food and Drug Administration | Ministry of Food and Drug Safety |
| Brands on the shelf | A short list of FDA-licensed products | Imported originals plus several Korean-made brands |
| How a dose is described | Often a unit count per area | Often an area package tied to one brand |
| Who injects | Set by state law; supervised nurse injectors are common | A doctor, as a medical procedure |
| Review at about two weeks | A local appointment | Only if the stay is long enough; otherwise photos from home |
Guide
Crow's feet as a test case for comparing products
Lines at the outer corner of the eye are a common test site for comparing toxins. Both papers took onabotulinumtoxinA as the reference.
In a 2015 split-face study in Dermatologic Surgery, Muti and Harrington treated 14 people with incobotulinumtoxinA on one side and onabotulinumtoxinA on the other at a one-to-one unit ratio, then swapped sides for a second cycle. Subjects and raters were blinded. Both sides improved to a similar degree at rest and on full squint, and the effect was still visible three months after each treatment.
In a 2020 Phase I/III trial in the same journal, Han and colleagues randomized 290 adults to HU-014, a newer toxin studied by a Korean team, or to onabotulinumtoxinA. In the Han trial, 72% in each group at week four reached the target score, meeting the noninferiority test, with no significant safety difference.
Guide
What those two trials settle and what they leave open
Both results describe one area, small doses and a fixed window. They show that a product sold in both countries, and a newer Korean product, kept pace with the American reference on crow's feet. They do not show that units convert one to one in the forehead, jaw or calves.
- The Muti study was small, so it shows a pattern rather than a precise figure.
- The Han trial followed people for 16 weeks after one treatment, not across years of repeat rounds.
Guide
Approved uses are listed product by product
In both countries a toxin is licensed for named uses, such as lines between the brows or around the eyes. Treating another area with the same product is off-label; that is lawful and common, but ask why. Korean labels are granted separately, so a brand's approved list in Korea need not match its American one. In either chair, ask which product is planned, which areas it is licensed for, and how the dose for any off-label area was chosen.
Guide
Consultation flow when the clinic is on an island
A US visit often starts with a scheduled consultation and may leave the injections for another day. On a Jeju trip, assessment, marking and treatment usually happen in one sitting, so arrive with your questions written down.
- Which brand is planned, and can the sealed vial be shown first?
- How many units go to each area, and will that appear on the record?
- Who will perform the injections?
- What happens if one side looks different after you have left Korea?
Guide
Follow-up from the island to a home in the US
Most US-bound travelers leave Jeju by way of Seoul, and the usual check at about two weeks falls after many are back at work. Booking toxin on the first or second day of a Jeju stay gives the effect time to show before departure. On a short stay, agree how the clinic will review photos sent later, and give your home injector the brand, units and date. Results vary from person to person.
Evidence
Research behind this page
- A Prospective Rater- and Subject-Blinded Study Comparing the Efficacy of IncobotulinumtoxinA and OnabotulinumtoxinA to Treat Crow's FeetDermatologic Surgery · 2015 · doi:10.1097/dss.0000000000000262
In a 14-subject split-face crossover study, incobotulinumtoxinA and onabotulinumtoxinA at a 1:1 ratio gave comparable crow's feet improvement and duration.
- Phase I/III Clinical Trial to Evaluate the Safety and Efficacy of a New Botulinum Toxin (HU-014) Versus OnabotulinumtoxinA in Subjects With Moderate-to-Severe Crow's Feet LinesDermatologic Surgery · 2020 · doi:10.1097/dss.0000000000002807
In 290 randomized subjects, 72% in both groups reached the week-4 crow's feet endpoint, supporting noninferiority of HU-014.
FAQ
Questions about Botox in Jeju
Can a US injector use the Korean toxin I received on Jeju for my next round?
Only if that product is sold in the United States, and many Korean brands are not. Nabota is the exception travelers meet most, because Daewoong markets it there as Jeuveau. For a Korea-only brand, your home injector will pick an FDA-licensed product and set the dose afresh. Bring the brand and units in writing so they can judge how strong the last round was.
What does split-face crossover mean in the Muti and Harrington study?
It means each person received one product on the right side and the other on the left, then the sides were swapped for the next cycle. Testing both products on the same face removes differences in age, skin and muscle strength between people. The trade-off is size: the 2015 study included 14 people. Read it as support for a one-to-one swap on crow's feet, not a rule for every area.
Is a toxin licensed only in Korea less tested than one licensed in the US?
Not necessarily, because a Korean license for a new toxin also rests on clinical trial data, as the 2020 Han trial of HU-014 illustrates. A missing US license may simply mean the maker never applied to the FDA. What a US resident gives up with a Korea-only brand is continuity, since the same product cannot be repeated at home. Ask which trials support the brand for your area.
How soon can I take the flight from Jeju to Seoul after crow's feet injections?
A short domestic flight later the same day is generally acceptable once you have stayed upright for a few hours. Cabin pressure does not shift toxin already bound to nerve endings. The larger question is the onward long-haul flight, because the result keeps developing for about two weeks. Avoid pressing on the eye area with a travel pillow or sleep mask on treatment day.
Is it worth asking for a brand licensed in both countries?
It is a reasonable request if you plan to repeat treatment at home, because one product keeps your unit history meaningful. Botox, Xeomin and Nabota, sold in the US as Jeuveau, are the brands a traveler can match on both sides. A Korea-only product is not a wrong choice, and trials such as the 2020 Han study support some of them. Results vary from person to person.